Add To Watchlist
Share URL
About The Company
CEO
Dr. Deborah Dunsire M.D.
Market Cap
29.83 Billion DKK
Sector
Healthcare
Website
https://www.lundbeck.comDescription
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally.
Read More
Overview
Value
81
Growth
28
Health
38
Management
66
Analyst Opinion
86
Total
60
All Scores Out Of 100
Best Features
- Has a low level of debt
- Has a history of share buybacks
- Price-to-earnings ratio of 8.8 is lower than the market average (19.6x)
- Has a margin-of-safety above fair value
- Liked by analysts
- Has high dividend yeild
- Low preportion of income is paid as dividend
Risk Factors
- Earnings have declined recently
- Does not hold enough liquid assets to cover short term liabilities
- Poor earnings and cashflow growth
- Very undervalued
Market Peers
HLUN-B.CO
Key Figures
PE Ratio (TTM)
8.76
Margin Of Safety (DCF)
194.25%
Revenue Growth (5 Year Average)
1.78%
Ratings Consensus
Strong Buy
Share Buybacks
0.01%
Dividend Yeild (TTM)
1.33%
Valuation
Value Score
81
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 143.9 DKK ✔
Current Price: 31.4 DKK
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
8.76x
Free Cashflow Yeild
9.03%
PE/Earnings Growth
N/A
Price/Book
1.44x
Growth
Growth Score
28
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Cashflow growth of 23.03% is higher than the market average (12.35%)
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of 1.78% is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of -15.32% is lower than the market average (14.48%)
- ✘ Earnings growth has slowed this year
Revenue Growth
1.78%
Earnings Growth
-15.32%
Cashflow Growth
23.03%
Health
Health Score
38
Altman Z Score
N/A
Piostroski Score
N/A
Debt/Equity
0.29x
Current Assets/Liabilities
0.98x
Free Cashflow/Total Debt
0.31x
Debt/Capital
0.62x
Dividend
Secure Dividend Score
63
- ✔ Dividend is likely safe
- ✔ Long term dividend payout ratio of 59.55% is considered good
- ✔ Payout ratio (TTM) of 20.72% is lower than the average (40%)
- ✔ Spending a lower percentage of their income on dividends than last 5 years
- ✘ Dividend yeild of 1.33% is less than the market average (1.85%)
- ✘ Dividends have been declining over the last 5 years
Dividend Yeild
1.33%
Dividend Growth
-19.80%
Payout Ratio (Earnings)
20.72%
Payout Ratio (Cashflow)
14.71%
Management
Management Score
66
- ✔ Has repurchased shares when value is good
- ✔ Has a history of returning value to shareholders through stock buybacks
- ✔ Has reduced dividends when earnings have fallen
- ✔ Return-on-equity of 34.54% is higher than the market average (15%)
- ✔ Return-on-capital-employed of 11.86% is higher than the market average (10%)
Average Buybacks/Dilution
0.01%
Recent Buybacks/Dilution
N/A
5 Year Price Volitility
N/A
Return On Assets
18.22%
Return On Capital Employed
11.86%
Return On Equity
34.54%
Return On Free Cashflow
187.95%
Return On Investments
11075.87%
Analysts
Analyst Opinion
86
- ✔ Ratings consensus is Strong Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Currency
DKK
Beta
Vol Avg
Ceo
Dr. Deborah Dunsire M.D.
Cik
Cusip
Exchange
Copenhagen
Full Time Employees
Industry
Drug Manufacturers—Specialty & Generic
Sector
Healthcare
Ipo Date
Address
Ottiliavej 9
City
Valby
State
Country
Zip
2500
Phone
45 36 30 13 11
All financial data provided by FMP